Events

Elrig Drug Discovery Digital w/ Amparo Toboso-Navasa

Endotype-driven target identification detection using omics data

Sam Abujudeh, Marika Catapano, Paidi Creed, Jaime Domingues, Craig Glastonbury, Josep Montserrat,  Francesca Mulas, Povilas Norvaisas, Delphine Rolando, Aaron Sim, Amparo Toboso-Navasa, Hamish Tomlinson, Arpad Vezer.


Cancer, sarcopenia, diabetes, and ALS, are but a few diseases that present notable heterogeneity between patients in both symptoms and aetiology. This heterogeneity extends to the patients’ response to experimental treatments, therefore presenting a significant challenge for drug discovery.

Embracing this challenge, at BenevolentAI we have developed an approach using omics data to identify patient subgroups. Here we present this approach, illustrated with a case study from our patient stratification drug discovery programs.

Unsupervised machine learning methods can be used to identify subgroup-specific patterns; the biological interpretation of these patterns is key for the identification of endotype-specific disease-modifying targets. We have developed a systematic evaluation of the identified patterns by assessing confounding variables, clinical covariates and biological mechanisms.  Therefore, biologically meaningful subgroup-specific patterns are defined by the lack of confounding effects, their correlation with clinical variables and their implication in biological pathways. 

Our pipeline tackles the challenges of interpreting subgroup-specific patterns derived from high-dimensional omics data, while uncovering pathobiological aspects of the disease specific to a group of patients. The identification of biological mechanisms that explain a given disease in different patient subgroups will facilitate drug discovery by providing targets regulating those mechanisms.


Amparo Toboso-Navasa

Drug Discovery Scientist

At BenevolentAI, Drug Discovery Scientists with Biology, Pharmacology and Chemistry backgrounds, work together with Bioinformaticians and AI Scientists.  With our joint effort,  we focus on identifying heterogeneous diseases that will benefit from our Precision Medicine approach. We look for omics datasets that reflect this heterogeneity while capturing clinical information; this will allow our models to find patient subgroups. Then, Drug Discovery Scientists, as myself, interpret the underlying biology to find disease drivers in each endotype. Target identification is followed by target validation in experimental settings that mimic the characteristics of each patient subpopulation so we find the right target for the right patient. 



More Posts

You Might Also Like

Blog
AI in Drug Discovery
This blog seeks to demystify the application of artificial intelligence (AI) and machine learning (ML) in drug discovery by exploring some of the challenges, opportunities and progress that has been achieved in the field so far.
Jul 13, 2021
News
BenevolentAI announces the appointment of biopharma luminary Dr François Nader as Chairman
Dr Nader joins BenevolentAI as it embarks on ambitious growth plans to scale its AI platform, partnerships and drug portfolio.
Jul 9, 2021
Blog
Product design in AI-drug discovery: how to design products for and with scientific users
User interfaces can help drug discovery scientists to leverage insights from AI algorithms. Yet, designing products to enable scientific discovery is complex. Our product designer, Róża explores the key steps in her design process.
Jul 6, 2021
News
Baricitinib, first identified by BenevolentAI as a COVID-19 treatment, is granted emergency use in India in response to its escalating crisis
Baricitinib - first identified by BenevolentAI as a potential COVID-19 treatment - is accelerated for use in hospitalised patients in India following a continued surge in cases and fatalities.
May 5, 2021
Video
A New Era in Target Discovery: Collaborating with AstraZeneca on CKD and IPF
Finding the right target underpins the success of the entire drug discovery process. Learn how BenevolentAI’s collaboration with AstraZeneca is making a difference in CKD and IPF.
Apr 23, 2021
News
Data from Eli Lilly’s COV-BARRIER trial shows baricitinib reduced deaths in hospitalised COVID-19 patients by 38%
The latest data published in Eli Lilly’s Phase 3 randomised, double-blind, placebo-controlled study (COV-BARRIER) shows the largest clinical effect reported to date for a reduction in mortality in the COVID-19 patient population
Apr 8, 2021